GAST Antibody

What is GAST and what role do GAST antibodies play in research?

GAST (gastrin) is a hormone primarily formed by mucosal cells in the gastric antrum and by D cells of the pancreatic islets. Its main function is to stimulate hydrochloric acid (HCl) secretion by the gastric mucosa. GAST also stimulates smooth muscle contraction and increases blood circulation and water secretion in the stomach and intestine .

GAST antibodies serve crucial roles in research:

• Detection and quantification of gastrin in biological samples

• Studying gastrin's role in GPCR signaling pathways

• Investigating gastrin's involvement in pathological conditions like Zollinger-Ellison syndrome

• Examining relationships between gastrin and tumor development

Human gastrin has a canonical length of 101 amino acid residues and a molecular weight of approximately 11.4 kilodaltons. It is primarily expressed in the stomach and is classified as a secreted protein belonging to the Gastrin/cholecystokinin protein family .

What types of GAST antibodies are available for research applications?

Several types of GAST antibodies are available for researchers:

Selection depends on your experimental goals, with monoclonal antibodies offering higher specificity and polyclonal antibodies providing greater epitope coverage. Validation status for different applications (IHC, ELISA, ICC, IF, WB) varies by product .

How do polyclonal and monoclonal GAST antibodies differ in research applications?

Polyclonal GAST Antibodies:

• Recognize multiple epitopes on the gastrin protein

• Generally provide stronger signals due to binding of multiple antibodies to the target

• Better for detecting denatured proteins in applications like Western blot

• Often used for initial screening or when target protein levels are low

• Example: Rabbit polyclonal anti-GAST antibody (A47134)

Monoclonal GAST Antibodies:

• Recognize a single epitope with high specificity

• Provide more consistent lot-to-lot reproducibility

• Superior for distinguishing between closely related proteins or specific gastrin forms

• Preferred for quantitative assays requiring high specificity

• Example: Mouse monoclonal antibody GAST/2634

For kinetic studies examining gastrin immunoneutralization, research has shown significant differences between full IgG and Fab fragments, with T1/2 values of 59.3 ± 3.5 h for IgG compared to only 7.3 ± 0.7 h for Fab fragments .

What is the optimal protocol for IHC staining using GAST antibodies?

Optimized IHC Protocol for GAST Antibodies:

• Tissue Preparation:

  • Fix tissue in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-6 μm thickness

• Antigen Retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Heat to 95-98°C for 15-20 minutes

  • Cool at room temperature for 20 minutes

• Blocking and Antibody Application:

  • Block endogenous peroxidase with 3% H₂O₂ for 10 minutes

  • Apply protein block (serum-free) for 30 minutes

  • Incubate with anti-GAST primary antibody (typically at 1:100-1:400 dilution, optimized for each antibody)

  • Use antibody diluent containing background reducing components

  • Incubate overnight at 4°C or 60 minutes at room temperature

• Detection and Visualization:

  • Apply appropriate secondary antibody conjugated to HRP

  • Visualize with DAB substrate

  • Counterstain with hematoxylin

• Controls:

  • Include gastric antrum tissue as positive control

  • Include isotype-matched antibody as negative control

For polyclonal antibodies like Anti-GAST (A47134), which are typically affinity purified, a working concentration of 0.4 mg/ml is recommended as a starting point, with optimization for each specific application .

How can researchers validate the specificity of GAST antibodies?

Comprehensive Validation Approach for GAST Antibodies:

• Western Blot Analysis:

  • Confirm single band at expected molecular weight (11.4 kDa for human gastrin)

  • Include positive control tissue (gastric antrum extracts)

  • Include recombinant gastrin protein as standard

  • Test specificity against related peptides (cholecystokinin)

• Immunoprecipitation:

  • Precipitate gastrin from tissue lysates

  • Confirm identity by mass spectrometry

• Peptide Competition Assay:

  • Pre-incubate antibody with excess synthetic gastrin peptide

  • Signal should be abolished/significantly reduced in immunoassays

• Knockout/Knockdown Controls:

  • Test antibody on tissues/cells with GAST gene knockout

  • Alternative: Use siRNA knockdown of GAST and confirm reduced signal

• Cross-reactivity Testing:

  • Test against gastrin precursors and metabolites

  • Test against related peptide hormones (CCK)

• Multiple Antibody Validation:

  • Compare results using antibodies recognizing different epitopes

  • Compare monoclonal vs. polyclonal results

• Orthogonal Detection Methods:

  • Correlate antibody detection with orthogonal methods (mRNA expression, mass spectrometry)

For accurate validation, researchers should apply multiple approaches as no single method provides conclusive evidence of specificity .

What controls should be used when working with GAST antibodies?

Essential Controls for GAST Antibody Experiments:

• Positive Tissue Controls:

  • Gastric antrum tissue (high gastrin expression)

  • Pancreatic tissue (D cells express gastrin)

  • G-cell neuroendocrine tumors

  • Each experimental batch should include positive control tissues

• Negative Tissue Controls:

  • Tissues known not to express gastrin

  • Tissues from GAST knockout models

• Antibody Controls:

  • Isotype control (matched IgG with irrelevant specificity)

  • Secondary antibody only (omit primary antibody)

  • Pre-immune serum (for polyclonal antibodies)

• Technical Controls:

  • Peptide competition controls (pre-absorb antibody with excess antigen)

  • Dilution series to establish optimal antibody concentration

  • Blocking peptide controls

• Quantification Controls:

  • Recombinant gastrin protein at known concentrations

  • Internal standard peptides for mass spectrometry validation

• Treatment Validation Controls:

  • For functional studies: anti-gastrin antibodies should inhibit gastrin-17 stimulated acid secretion but not histamine-stimulated secretion, as demonstrated in immunoneutralization studies

Proper controls are critical for distinguishing true signals from technical artifacts, especially in complex tissues where gastrin expression varies considerably .

How do the kinetics of gastrin immunoneutralization differ between full IgG and Fab fragments?

Research on gastrin immunoneutralization demonstrates significant kinetic differences between full IgG antibodies and their Fab fragments:

Full IgG Anti-Gastrin Antibodies:

• Half-life (T1/2): 59.3 ± 3.5 hours

• Sustained inhibition period: Up to 48 hours after the last dose

• Administration method: Effective via intraperitoneal (IP) injection

• Absorption rate: ~70% of administered dose absorbed (peak levels at 8h post-administration)

• Duration of effectiveness: Can maintain immunoneutralization for up to 16 days with alternate-day IP injections

• Biological indicators: Specifically inhibit gastrin-17 stimulated acid secretion without affecting histamine-stimulated secretion

Fab Fragments:

• Half-life (T1/2): 7.3 ± 0.7 hours (approximately 8 times shorter than full IgG)

• Inhibition period: Complete inhibition at 4 hours post-administration

• Duration: Effects not observed 24 hours after administration

• Administration method: Effective via intravenous (IV) administration

• Target specificity: Maintain target specificity (block gastrin-17 but not histamine stimulation)

These kinetic differences are critical for experimental design when targeting gastrin in research models. The significantly shorter half-life of Fab fragments makes them suitable for acute studies requiring precise temporal control, while full IgG antibodies are preferable for chronic neutralization studies requiring sustained activity .

What approaches can be used to quantify gastrin levels using GAST antibodies?

Advanced Methods for Gastrin Quantification:

• Competitive ELISA:

  • Principle: Competition between sample gastrin and labeled gastrin for limited antibody binding sites

  • Detection range: 5-1000 pg/ml

  • Sample preparation: Acid extraction of tissue samples or direct serum measurement

  • Advantages: High throughput, relatively simple procedure

  • Considerations: May be affected by cross-reactivity with gastrin precursors

• Sandwich ELISA:

  • Principle: Capture and detection antibodies recognizing different gastrin epitopes

  • Improved specificity: Can distinguish between different gastrin forms

  • Requirements: Two non-competing antibodies (e.g., GAST/2634 and GAST/2633)

  • Sensitivity: Can achieve <1 pg/ml detection limits

  • Advantages: Higher specificity than competitive ELISA

• Radioimmunoassay (RIA):

  • Traditional gold standard for gastrin quantification

  • Uses radiolabeled gastrin and anti-gastrin antibodies

  • Sensitivity: 2-5 pg/ml

  • Limitations: Radioisotope handling requirements

• Immunohistochemical Quantification:

  • Semi-quantitative assessment of gastrin-producing cells

  • Digital image analysis for cell counting and intensity measurement

  • Applications: Tissue distribution studies, pathology assessment

  • Limitations: Not truly quantitative for systemic levels

• Multiplex Immunoassay:

  • Simultaneous measurement of gastrin alongside other GI hormones

  • Platform examples: Luminex, MSD

  • Advantages: Reduced sample volume, assessment of multiple analytes

  • Considerations: Potential for cross-reactivity

• Mass Spectrometry with Immunocapture:

  • Combines antibody specificity with MS identification

  • Can distinguish between different gastrin forms (G17, G34, etc.)

  • Provides absolute quantification

  • Requires specialized equipment and expertise

What are the latest advancements in generating highly specific GAST antibodies?

Recent technological advancements have revolutionized antibody generation, including those targeting gastrin:

1. Autonomous Hypermutation Yeast Surface Display (AHEAD):

• This innovative approach combines orthogonal DNA replication, yeast surface display, and fluorescence-activated cell sorting

• Creates antibodies with desired characteristics without animal immunization

• Employs error-prone DNA polymerase with mutation rates 100,000-fold higher than genomic mutation rates

• Enables parallel evolution of multiple clones simultaneously

• Significantly reduces development time (high-affinity antibodies in as little as three days)

• Suitable for generating anti-gastrin antibodies with precisely defined binding profiles

• Addresses ethical concerns associated with animal immunization

2. Deep Learning-Based Antibody Design:

• Computational generation of antibody libraries with "medicine-like" properties

• Training on datasets of antibodies pre-screened for high humanness and low chemical liabilities

• Wasserstein Generative Adversarial Network with Gradient Penalty (WGAN+GP) models create novel sequences

• In-silico sequences maintain developability attributes when produced as physical antibodies

• Experimental validation confirms high expression, monomer content, and thermal stability

• Applied to create gastrin-specific antibodies with optimized biophysical properties

3. Structure-Based Design and Prediction:

• Advanced computational modeling of antibody-antigen interactions

• Tools like tFold-Ab for antibody structure prediction and tFold-Ag for antibody-antigen complex prediction

• Direct atomic-resolution structure prediction from sequence information

• Enables virtual screening of binding antibodies against gastrin

• Supports de novo co-design of structure and sequence for therapeutic anti-gastrin antibodies

4. Antibody Libraries with Customized Specificity Profiles:

• Phage display selection combined with computational modeling

• Training on multiple datasets to build predictive models for antibody specificity

• Design of antibodies that can distinguish between closely related ligands

• Particularly valuable for gastrin research, where distinguishing between gastrin and cholecystokinin can be challenging

These technologies represent significant advances that facilitate faster, more ethical, and potentially more successful generation of highly specific GAST antibodies .

How can computational approaches assist in designing GAST antibodies with improved specificity?

Computational Strategies for Optimizing GAST Antibody Specificity:

• Machine Learning-Based Sequence Design:

  • Generative models (WGAN+GP) can create novel antibody sequences

  • Training on pre-screened antibody datasets with desirable properties

  • Generation of 31,416 IGHV3-IGKV1 antibody variable region sequences

  • Filtering for medicine-likeness and humanness scores (>90th percentile)

  • Experimental validation confirms computational predictions of stability and specificity

  • Applied to gastrin targeting: selecting sequences with predicted high affinity for gastrin but low cross-reactivity with related peptides

• Structure-Based Modeling and Design:

  • Fast and accurate prediction of antibody-antigen complex structures (tFold-Ag)

  • DockQ scores of 0.217 and TM-scores of 0.708, outperforming existing methods

  • Higher successful rate (0.283) compared to AlphaFold-Multimer (0.182)

  • Enables structure-based virtual screening of binding antibodies

  • De novo co-design of structure and sequence for therapeutic antibodies

  • Modeling of gastrin epitopes to design complementary paratopes

• Epitope Mapping and Paratope Design:

  • Computational identification of unique gastrin epitopes

  • Distinguishing gastrin from related peptides (e.g., cholecystokinin)

  • Design of complementary binding regions in antibody variable domains

  • Energy minimization to optimize binding interface

  • Prediction of binding affinity and cross-reactivity

• Antibody Specificity Inference:

  • Models built from phage display experiments with antibody libraries

  • Training and test sets from selection against various ligand combinations

  • Prediction of novel antibody sequences with customized specificity profiles

  • Application to design antibodies that specifically recognize gastrin but not related hormones

These computational approaches reduce reliance on traditional animal immunization methods while potentially delivering antibodies with superior specificity, affinity, and developability characteristics. This is particularly valuable for gastrin research, where distinguishing between closely related gastrointestinal peptide hormones remains challenging .

How do researchers troubleshoot non-specific binding with GAST antibodies?

Systematic Approach to Resolving Non-Specific Binding Issues:

• Antibody Source Evaluation:

  • Compare monoclonal vs. polyclonal antibodies

  • Monoclonal GAST antibodies (e.g., GAST/2634, GAST/2633) offer greater specificity

  • Test multiple antibody clones recognizing different epitopes

  • Consider antibody format (full IgG vs. Fab fragments) - Fab fragments may reduce Fc-mediated non-specific binding

• Protocol Optimization:

  • Blocking Optimization:

    • Test different blocking agents (BSA, casein, commercial blockers)

    • Extend blocking time (1-2 hours at room temperature)

    • Add 0.1-0.5% Tween-20 to reduce hydrophobic interactions

  • Antibody Dilution Series:

    • Titrate antibody concentration to determine optimal signal-to-noise ratio

    • For Anti-GAST antibody (A47134), start with recommended 0.4 mg/ml working concentration

    • Gradual dilutions to identify minimal effective concentration

  • Buffer Modifications:

    • Increase salt concentration (150mM to 300mM NaCl) to reduce ionic interactions

    • Add carrier proteins (0.1-0.5% BSA)

    • Add non-ionic detergents (0.05-0.1% Triton X-100)

• Advanced Validation Techniques:

  • Peptide Competition Assay:

    • Pre-incubate antibody with:

      • Specific antigen (gastrin peptide) - should eliminate specific binding

      • Unrelated peptides (should not affect specific binding)

    • Monitor signal reduction patterns to distinguish specific from non-specific binding

  • Knockout/Knockdown Controls:

    • Test antibody on GAST-knockout tissues or cells

    • Use siRNA knockdown of GAST expression

    • All specific signal should be significantly reduced

• Cross-Reactivity Management:

  • Gastrin-Related Peptides:

    • Pre-absorb antibody with cholecystokinin peptides

    • Test antibody against gastrin precursors and fragments

    • Document cross-reactivity profile for accurate data interpretation

  • Cross-Adsorption:

    • Pre-incubate antibody with tissue homogenates lacking gastrin

    • Remove antibodies binding to non-gastrin epitopes

• Environmental Factors:

  • Temperature Control:

    • Perform incubations at 4°C to reduce non-specific binding

    • Compare room temperature vs. 4°C protocols

  • Incubation Time Optimization:

    • Shorter primary antibody incubation may reduce non-specific binding

    • Test 1-2 hour room temperature vs. overnight 4°C incubation

Each troubleshooting approach should be systematically documented and compared to identify the optimal conditions for specific GAST detection in your experimental system.

What are the emerging applications of GAST antibodies in cancer research?

GAST Antibodies in Cancer Research: Current Applications and Future Potential

• Gastrin-Dependent Tumor Targeting:

  • Gastrin and gastrin-releasing peptide (GRP) act as autocrine growth factors for certain cancer cell types

  • GAST antibodies can disrupt this signaling pathway

  • Immunoneutralization of gastrin inhibits growth of gastrin-dependent tumors

  • Differential effects of antibody formats: full IgG provides sustained neutralization (T1/2: 59.3 ± 3.5h) while Fab fragments offer precise temporal control (T1/2: 7.3 ± 0.7h)

• Diagnostic Applications:

  • Detection of elevated gastrin expression in:

    • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

    • Zollinger-Ellison syndrome

    • Certain colorectal cancers

  • Correlation of gastrin expression with tumor aggressiveness and treatment response

  • Immunohistochemical classification of tumor subtypes

• Therapeutic Development:

  • Anti-gastrin antibodies as direct therapeutic agents

  • Combined targeting of gastrin and gastrin-releasing peptide (GRP)

  • Antibody-drug conjugates delivering cytotoxic payloads to gastrin-expressing cells

  • CAR-T cell therapy using gastrin-targeting antibody fragments

• Pulmonary Neuroendocrine Research:

  • GRP stimulates gastrin release and acts as autocrine growth factor

  • Elevated GRP levels in lung cancer correlate with neuroendocrine differentiation

  • Monitoring changes in pulmonary neuroendocrine cells after birth

  • GAST antibodies for studying lung tumorigenesis in model systems

• Precision Medicine Applications:

  • Identification of patients likely to respond to anti-gastrin therapies

  • Monitoring treatment response via circulating gastrin levels

  • Development of companion diagnostics for anti-gastrin therapeutics

• Novel Antibody Technologies:

  • Deep learning-generated antibodies with medicine-like properties targeting gastrin

  • Computationally designed antibodies with optimized binding profiles

  • AHEAD (Autonomous Hypermutation Yeast Surface Display) for rapid development of gastrin-targeting antibodies

These emerging applications represent significant opportunities for using GAST antibodies to advance both fundamental cancer biology understanding and clinical oncology practice.

How do antibody-based detection methods for GAST compare to alternative technologies?

Comparative Analysis of GAST Detection Methods:

Key Considerations for Method Selection:

• Scientific Question:

  • For tissue localization: Immunohistochemistry using validated GAST antibodies

  • For absolute quantification: Mass spectrometry or radioimmunoassay

  • For high-throughput screening: ELISA with monoclonal GAST antibodies

• Sample Type:

  • Serum/Plasma: ELISA, RIA or mass spectrometry

  • Tissue: Immunohistochemistry or mass spectrometry imaging

  • Cell culture: Immunofluorescence, ELISA of culture media

• Distinguishing Gastrin Forms:

  • When differentiating between gastrin variants is crucial, mass spectrometry provides superior resolution

  • Antibodies with known epitope specificity can partially differentiate some forms

• Resource Considerations:

  • Equipment availability

  • Budget constraints

  • Technical expertise requirements

• Emerging Technologies:

  • Computational antibody design is generating highly specific GAST antibodies

  • Multiplexed detection platforms allow simultaneous measurement of gastrin alongside other biomarkers

For optimal results, researchers often employ multiple complementary methods to validate findings and overcome the limitations of individual techniques.

How is computational biology transforming GAST antibody development?

Computational Revolution in GAST Antibody Engineering:

Recent technological breakthroughs are fundamentally changing how GAST antibodies are developed, representing a shift from traditional discovery to rational design:

• Deep Learning Antibody Generation:

  • WGAN+GP models trained on 31,416 pre-screened antibody sequences

  • Generation of 100,000 novel variable region sequences with medicine-like properties

  • Computational screening for developability attributes before wet-lab validation

  • Experimental confirmation of computational predictions: high expression, monomer content, thermal stability

  • Potential to design anti-gastrin antibodies with customized binding profiles

• Structure-Based Design and Prediction:

  • tFold-Ab and tFold-Ag platforms predict antibody structures and antibody-antigen complexes

  • End-to-end atomic-resolution structure prediction directly from sequence

  • Superior performance metrics: DockQ score of 0.217 and TM-score of 0.708

  • Higher successful rate (0.283) compared to alternative methods

  • Applications include virtual screening and de novo antibody design targeting gastrin

• Integration of Multiple Data Types:

  • Combining sequence, structure, and experimental binding data

  • Machine learning models predicting specificity based on sequence features

  • Integration of phage display selection data with computational inference

  • Design of antibodies with customized specificity profiles

  • Particularly valuable for distinguishing gastrin from related peptides

• Advantages Over Traditional Methods:

  • Reduced reliance on animal immunization

  • Faster development timeline (days vs. months)

  • Ability to design antibodies against difficult targets

  • Systematic exploration of sequence space beyond natural antibody repertoires

  • Optimization for multiple parameters simultaneously (affinity, specificity, developability)

• Future Directions:

  • Integration of experimental feedback into model refinement

  • End-to-end platforms combining computational design with automated experimental validation

  • Design of antibodies that can specifically distinguish between gastrin forms

  • Development of antibodies targeting conformational epitopes on gastrin

  • AI-driven optimization of antibody therapeutic properties

These computational approaches represent a paradigm shift that could fundamentally transform how researchers develop GAST antibodies, potentially leading to more precise reagents for research and more effective therapeutics.

What are the challenges in developing therapeutic antibodies targeting the GAST pathway?

Critical Challenges in Developing Anti-GAST Therapeutics:

• Target Complexity Issues:

  • Gastrin Heterogeneity:

    • Multiple forms exist (G17, G34, progastrin, C-terminal amidated fragments)

    • Each variant may have distinct biological activities

    • Antibodies must target relevant forms for therapeutic efficacy

    • Challenge: Designing antibodies specific for clinically relevant forms

  • Pathway Redundancy:

    • Alternative signaling pathways may compensate for GAST inhibition

    • Cross-talk between gastrin and cholecystokinin pathways

    • Targeting gastrin alone may not provide complete pathway inhibition

    • Challenge: Identifying optimal combination approaches

• Pharmacokinetic/Pharmacodynamic Considerations:

  • Antibody Penetration:

    • Limited tissue penetration of full IgG antibodies

    • Variable access to target sites

    • Challenge: Optimizing antibody format (full IgG vs. Fab fragments)

    • Different kinetic profiles: T1/2 of 59.3 ± 3.5h for IgG vs. 7.3 ± 0.7h for Fab fragments

  • Dosing Strategies:

    • Finding optimal dosing for sustained gastrin neutralization

    • Balancing efficacy with off-target effects

    • Challenge: Translating preclinical pharmacology to human dosing

• Development and Manufacturing Challenges:

  • Stability and Developability:

    • Optimizing antibody sequences for stability and expression

    • Minimizing aggregation and immunogenicity risks

    • Challenge: Designing antibodies with both optimal target binding and excellent developability profiles

  • Production Considerations:

    • Consistent manufacturing of complex biologics

    • Scale-up from research to clinical production

    • Challenge: Maintaining binding characteristics across manufacturing processes

• Clinical Development Hurdles:

  • Patient Selection:

    • Identifying patients likely to respond to anti-gastrin therapy

    • Developing biomarkers for patient stratification

    • Challenge: Creating companion diagnostics for patient selection

  • Efficacy Evaluation:

    • Defining appropriate clinical endpoints

    • Long development timelines for cancer therapeutics

    • Challenge: Designing trials to demonstrate clinical benefit

• Emerging Solutions:

  • Computational Approaches:

    • Machine learning models for predicting antibody properties

    • Structure-based design of optimized binding interfaces

    • In-silico prediction of cross-reactivity and off-target binding

    • Challenge: Validating computational predictions in biological systems

  • Advanced Antibody Formats:

    • Bispecific antibodies targeting multiple epitopes

    • Antibody-drug conjugates for enhanced potency

    • Format engineering for improved tissue penetration

    • Challenge: Balancing complex formats with manufacturability